Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Transmitted Diseases, Viral Clear all
Completed Phase 1 Interventional

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

NCT00000725
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Early Phase 1 Interventional

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

NCT02823847
View directory record Official record
Conditions
Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus
Interventions
Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy
Behavioral · Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

NCT04177355
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects

NCT00004578
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
10
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

NCT00002243
View directory record Official record
Conditions
HIV Infections
Interventions
Calanolide A
Drug
Lead sponsor
Sarawak MediChem Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Miami, Florida • Vero Beach, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:57 AM EDT
Completed No phase listed Observational

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

NCT03218085
View directory record Official record
Conditions
HIV/AIDS, Menopause, Inflammation Vagina
Interventions
Tenofovir, Emtricitabine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 16, 2026, 9:57 AM EDT
Completed No phase listed Observational

Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)

NCT03572335
View directory record Official record
Conditions
HIV Infections, Pulmonary Disease
Interventions
PFT's (pulmonary function testing)
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 16, 2026, 9:57 AM EDT
Terminated Phase 4 Interventional

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

NCT00100984
View directory record Official record
Conditions
HIV Infection
Interventions
FUZEON [enfuvirtide]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
20
States / cities
Hobson City, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 4 Interventional

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00005106
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional

Text Education About Cardiovascular Health and HIV (TEACH-HIV)

NCT05642858
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus, Cardiovascular Diseases, Atherosclerosis
Interventions
Digital Educational Messaging
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 16, 2026, 9:57 AM EDT
Completed No phase listed Observational

Case-Control Viramune (Nevirapine) Toxicogenomics Study

NCT00310843
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Baltimore, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Not applicable Interventional

The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

NCT00152061
View directory record Official record
Conditions
HIV Infections
Interventions
3TC and FTC
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 16, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The TAIL-PrEP Study

NCT06868641
View directory record Official record
Conditions
HIV Infections
Interventions
TAIL-PrEP for patients discontinuing cab-LA, TAIL-PrEP for patients considering discontinuing cab-LA, TAIL-PrEP for patients considering discontinuing LEN
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

NCT00887653
View directory record Official record
Conditions
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

HIV and STD Prevention for High-Risk, Inner-City, African American Youth

NCT00353405
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Social Skills Training, Mass media, Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 17 Years
Enrollment
1,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Syracuse, New York • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 16, 2026, 9:57 AM EDT
Completed No phase listed Observational

The Visceral Adiposity Measurement and Observation Study

NCT05383456
View directory record Official record
Conditions
HIV, HIV-Infections, HIV-1-infection, HIV I Infection, HIV Lipodystrophy, HIV Infection Primary, HIV-Associated Lipodystrophy, HIV Disease Progression, Lipohypertrophy, Liver Diseases, NAFLD, NASH, Liver Fibrosis, Hepatic Fibrosis, Waist Circumference, BMI, Ectopic Fat, Liver Fat, Hepatic Steatosis
Interventions
Diagnostic Test, HIV Anti-retroviral Background Therapy
Diagnostic Test · Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 16, 2026, 9:57 AM EDT
Completed No phase listed Observational

HIV Resistance and Treatment Strategies

NCT00581802
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US

NCT04832477
View directory record Official record
Conditions
HIV Seropositivity, Substance Use, STI, Stigma, Social
Interventions
Stigma counseling for PrEP use
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

NCT00002057
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Birmingham, Alabama • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

NCT00002322
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

NCT00056641
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, saquinavir, amprenavir, lopinavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children

NCT00000837
View directory record Official record
Conditions
HIV Infections
Interventions
Varicella Virus Vaccine (Live)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 8 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 16, 2026, 9:57 AM EDT
Recruiting Phase 2 Interventional

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

NCT06210854
View directory record Official record
Conditions
HPV Infection
Interventions
pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses)
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

NCT00002131
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Vesnarinone
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 9:57 AM EDT